Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.35 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10202983 | 1.00 | SCN9A (0.37) | SCN9ASLC22A12ADRA2AADRA2BADRA2C | |
| SCHEMBL15677574 | 0.86 | USP1 (0.39) | SCN9ASLC22A12ADRA2AADRA2BADRA2C | |
| SCHEMBL10263874 | 0.86 | USP1 (0.39) | SCN9ASLC22A12ADRA2AADRA2BADRA2C | |
| SCHEMBL30503590 | 0.77 | ALDH1A1 (0.43) | SLC22A12ADRA2AADRA2BADRA2CNFE2L2 | |
| SCHEMBL23358163 | 0.74 | SCN9A (0.43) | SCN9ASLC22A12ADRA2AADRA2BADRA2C | |
| SCHEMBL28202257 | 0.72 | SLC22A12 (0.47) | SCN9ASLC22A12NFE2L2SSTR4SSTR1 | |
| SCHEMBL30440802 | 0.71 | SLC22A12 (0.55) | SLC22A12NFE2L2ALDH1A1MAPTATM | |
| SCHEMBL322870 | 0.71 | SLC22A12 (0.55) | SLC22A12NFE2L2ALDH1A1MAPTATM | |
| SCHEMBL30783187 | 0.70 | DHODH (0.42) | SCN9ASLC22A12NFE2L2SSTR4SSTR1 | |
| SCHEMBL15677613 | 0.69 | SLC22A12 (0.44) | SLC22A12NFE2L2SSTR4SSTR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079901-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-03-19 | — | — | US | disclosed |
| US-8703759-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | GILEAD SCIENCES, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | GILEAD SCIENCES, INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, CACNA1E | SCN9A 91/4885SLC22A12 1145/4885ADRA2A 364/4885 |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | KCNJ2, KCNH2, CACNA1E | SCN9A 91/4885SLC22A12 1145/4885ADRA2A 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.